People · Operator
Named in public records as an officer, director or promoter · active 2008–2020 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Pliant Therapeutics, Inc. | — | Biotechnology | Series D+ | $162.6M | $4.1B | 2018 |
| Portola Pharmaceuticals Inc | — | Pharmaceuticals | Series C | $158.1M | $315.8M | 2008 |
| MyoKardia Inc | — | Biotechnology | Series C | $60.0M | $1.9B | 2012 |
| Faze Medicines, Inc. | — | Biotechnology | Series B | $30.4M | $999.5M | 2020 |
Charles Homcy at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Charles Homcy on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James Topper | 1 | 12 |
| Russell Hirsch | 1 | 10 |
| Robert Tepper | 1 | 7 |
| Hoyoung Huh | 1 | 7 |
| JEFF BIRD | 1 | 7 |
| Nicholas Galakatos | 1 | 6 |
| Jean George | 1 | 6 |
| Mark Perry | 1 | 6 |
| Farah Champsi | 1 | 5 |
| Alan Frazier | 1 | 5 |
| NEIL EXTER | 1 | 5 |
| Kevin Starr | 1 | 5 |
| Kevin Raidy | 1 | 4 |
| Cary Pfeffer | 1 | 4 |
| Gayle Crowell | 1 | 3 |
| Katherine Bowdish | 1 | 3 |
| Suzanne Bruhn | 1 | 2 |
| John Curnutte | 1 | 2 |
| Bernard Coulie | 1 | 2 |
| Smital Shah | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.